Money, explained for the rest of us.

Get our free daily email →

Generic-drug settlement offers two payment options, claims due March 8

By

Image Credit: Etatics Inc. - Pexels License/Pexels

People who bought a listed generic drug between May 2009 and December 2019 can file for money from the generic-drug price-fixing settlements by choosing between two payment options, and the second can never pay less than the first. Option 1 is an equal share with other claimants. Option 2 is a share based on estimated spending. The claim deadline for both is March 8, 2027.

The settlements were won by 48 attorneys general against drugmakers accused of rigging generic prices. California Attorney General Rob Bonta’s office put the settlements at about $96.5 million. The choice between the two options is the part of the claim form that decides how a payment is figured, and a claimant who skips it lands in Option 1.

Two ways to file the same claim

The settlement notice lays out the choice. Option 1 pays an equal share among everyone who picks it and asks for no spending estimate. Option 2 pays a share based on the claimant’s estimated out-of-pocket spending on the listed drugs during the period, and the notice says that payment “will not be less than” what Option 1 pays.

Claimants who make no choice are placed in Option 1. Final amounts for either option depend on how many valid claims arrive, and no per-person figure has been set. California’s release says only that the plan “aims to return millions of dollars” to people who paid inflated prices.

That makes the spending estimate the decision. A person who filled generic prescriptions regularly between 2009 and 2019, and can make a reasonable estimate of what they paid out of pocket, has a reason to choose Option 2, since it cannot pay less. Someone who cannot recall any spending can still file under Option 1 with no estimate at all. The estimate covers only the listed drugs during the settlement period, not every prescription a person filled, and it counts what the claimant paid out of pocket rather than what an insurer paid.

No receipts with the claim

The notice says no receipts are needed to file. It adds that the claims administrator may later ask for documentation behind an Option 2 estimate, which makes an honest estimate the safer one. Claims can be filed online at AGGenericDrugs.com, or a paper form can be requested by phone at 1-866-290-0182, by email at [email protected] or by mail.

The claims period opened September 22, 2026. A claimant whose form is incomplete gets 21 calendar days from the administrator’s notice to fix it, and the notice gives the same 21 days to appeal a rejection. Payment can come by PayPal, Venmo, Zelle or mailed check, and the notice gives 180 days to cash a payment. The notice encourages electronic payment and warns that mailed checks may be delayed by months.

Where residence changes the rules

Eligibility turns on the state or jurisdiction where the claimant lives when the claim is submitted, not where the drugs were bought. The District of Columbia, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands joined the states in the coalition, according to the New York attorney general’s release.

Residents of Alabama, Arkansas, Hawaii and Texas are eligible only for the Apotex settlement. They receive a fixed amount to be set later and do not choose between options. For everyone else, the notice names settlements with Heritage Pharmaceuticals, Emcure and Satish Mehta, Apotex, Bausch, Lannett and Glenmark. As of July 31, the notice said Glenmark’s settlement was still awaiting court approval.

What the cases covered and when money could arrive

The New York release says the cases cover more than 100 generic drugs, and that some coordinated price increases topped 1,000 percent. It says Heritage’s digoxin tripled in price. The full list of drugs is on the claims administrator’s site, and the claim form asks about purchases in the May 2009 to December 2019 window.

Three state lawsuits sit behind the settlements. A 2016 complaint named 18 corporate and two individual defendants over 15 generic drugs. A 2019 complaint named 22 manufacturers and 16 senior executives. A 2020 complaint named 26 corporate and 10 individual defendants over 80 topical generic drugs. The settling companies agreed to cooperate in the ongoing cases and to make compliance changes, the release says, and seven pharmaceutical executives have cooperated with the states.

The U.S. District Court for the District of Connecticut gave preliminary approval this fall to the plan for distributing the money, California’s release says. The notice sets the final approval hearing for September 8, 2027, at 10 a.m. in Hartford and says the date can change. None of the releases or the notice gives a payment date.

The open question for a claimant is whether a particular prescription is on the list and what it cost over those years. The administrator’s phone line and site answer the first part, and a claimant’s own pharmacy or insurance statements answer the second.

This article was produced with AI assistance and edited for accuracy against the sources linked above.


Spotted an error? Tell us at [email protected]. We fix mistakes fast and in the open — see how we work on our standards page.